Results 101 to 110 of about 205,027 (361)
Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. [PDF]
, 2020 AimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.MethodsThis was a retrospective case-control study of a ...
Amador-Patarroyo, Manuel J +6 more
core
Tuning Cellular Perception in Pluripotent Stem Cells through Topography, Stiffness, and Patterning
Advanced NanoBiomed Research, EarlyView.Micro‐ and nanotopographical cues, substrate stiffness, and mechanical patterning synergistically direct pluripotent stem cell fate and function by tuning cellular perception at the biointerface. Pluripotent stem cells (PSCs), comprised of embryonic stem cells and induced PSCs, hold tremendous therapeutic potential.
Yuan Jiang +7 more
wiley +1 more source
Age-related macular degeneration: current treatments
Clinical Ophthalmology, 2009 Jean Pierre Hubschman, Shantan Reddy, Steven D SchwartzJules Stein Eye Institute, Department of Ophthalmology, University of California, David Geffen School of Medicine, Los Angeles, California, USAPurpose: Although important progress has been made in ...
Jean Pierre Hubschman +2 more
doaj
Age-Related Macular Degeneration: A Complementopathy? [PDF]
Ophthalmic Research, 2015 Age-related macular degeneration (AMD) is a progressive eye disease affecting many elderly individuals. It has a multifactorial pathogenesis and is associated with numerous environmental (e.g. smoking, light and nutrition) and genetic risk factors. A breakthrough in the mechanisms causing AMD is emerging; the involvement of the alternative pathway of ...
Kijlstra, A., Berendschot, T.T.J.M.
openaire +3 more sources
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Biomedical Papers, 2015 Aims: The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods: Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database.
Oldrich Chrapek +8 more
doaj +1 more source
Mechanisms of Age-Related Macular Degeneration [PDF]
Neuron, 2012 Age-related macular degeneration (AMD), a progressive condition that is untreatable in up to 90% of patients, is a leading cause of blindness in the elderly worldwide. The two forms of AMD, wet and dry, are classified based on the presence or absence of blood vessels that have disruptively invaded the retina, respectively.
Benjamin J. Fowler, Jayakrishna Ambati
openaire +3 more sources
British Journal of Clinical Pharmacology, EarlyView.Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr +18 more
wiley +1 more source
Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage. [PDF]
, 2017 Age-related macular degeneration (AMD) ranks third among the leading causes of visual impairment with a blindness prevalence rate of 8.7%. Despite several treatment regimens, such as anti-angiogenic drugs, laser therapy, and vitamin supplementation ...
Chwa, Marilyn +6 more
core +1 more source